Leerink reiterates Hims and Hers stock rating on peptide outlook By Investing.com

Leerink Partners kept a Market Perform rating on Hims & Hers and a $25 price target, below the current $26.60 share price, while viewing an FDA Advisory Committee review of injectable peptides as a constructive catalyst. The committee will consider lifting restrictions on seven peptides across obesity, insomnia, migraines, and wound healing, which could support a longer-term growth path as personalized GLP-1 compounding fades. The development is positive but not immediately revenue-accretive, so near-term financial impact appears limited.

Analysis

The market is treating this as an optionality event, not an earnings event. If the FDA process loosens, the incremental value is less about near-term peptide revenue and more about preserving HIMS’ ability to keep cohorts engaged while the compounding-led growth engine rolls off; the key second-order effect is higher patient retention and more frequent lab utilization, which can partially offset the margin dilution from moving toward commercial sourcing. That said, this is still a binary regulatory catalyst with a long runway: committee sentiment can move the multiple in days, but real financial impact likely lands over quarters, not weeks.

The competitive winner is not just HIMS; it is any platform with an owned fulfillment and consumer-acquisition stack that can bundle peptides with diagnostics and follow-on care. Suppliers of commercial GLP-1s and contract manufacturers are the structural winners if demand shifts away from compounded supply, while pure-play telehealth competitors without proprietary dispensing infrastructure risk lower differentiation and weaker gross margin leverage. The hidden loser could be consumer-facing wellness brands that rely on cheap compounding economics — if the category normalizes into regulated commercial drugs, CAC payback periods likely lengthen across the sector.

Consensus looks too focused on the headline lift and not enough on margin math. A favorable committee outcome may actually compress the valuation gap if investors conclude the growth path becomes less profitable, not more, as the mix shifts toward lower-contribution products. The stock can still overshoot higher on short-covering and retail momentum, but that upside is likely tactical unless management can prove peptide-led lab volume creates a durable cross-sell loop.

The main reversal risk is not an outright negative FDA view; it is a tepid or delayed decision that preserves uncertainty while allowing the stock to fade as the near-term catalyst passes. If the committee is supportive but the implementation timeline is slow, the trade becomes a sell-the-news setup with downside over 1-3 months as investors refocus on margin pressure and competitor pricing.

Key Decisions for Investors

• Tactically long HIMS into the advisory committee date only if borrow is tight and options implied volatility is not already excessive; prefer call spreads to cap downside because the event is binary and likely to mean-revert after the headline.
• If HIMS rallies sharply on a favorable readout, trim into strength and consider a 1-3 month short against a basket of profitable digital health names; the risk/reward shifts once the market starts pricing lower-margin commercial mix rather than growth optionality.
• Pair trade: long a commercial GLP-1 beneficiary with owned distribution/manufacturing exposure against HIMS over 3-6 months; the thesis is that regulated supply-chain control wins when compounding economics fade.
• Avoid chasing HIMS common after a committee-friendly headline; use any post-event pop to sell call spreads or buy puts for a later fade if guidance does not raise gross margin assumptions within the next earnings cycle.
• Monitor for a multi-week follow-through in lab volume and repeat prescription data; if there is no measurable engagement lift by the next quarter, the regulatory win should be treated as a multiple-only event, not a fundamental re-rating.